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	 The	present	study	describes	the	chemical	synthesis	and	antimicrobial	evaluation	of	some	new
pyridazine	 and	 triazolopyridazine	 derivatives.	 The	 structure	 assignments	 of	 the	 new
compounds	 are	 based	 on	 chemical	 and	 spectroscopic	 evidences.	 The	 Study	 results	 showed
that	 derivatives	 6a,	 6b,	 6g	 and	 6i	 have	 promising	 inhibitory	 activity	 against	 (Micrococcus
luteus).	 Compound	 6i	 has	 also	 noticeable	 inhibition	 activity	 against	 (Escherichia	 coli)	 and
compound	 3g	 show	 remarkable	 activity	 against	 (Candida	 albicans).	 Rest	 of	 compounds
showed	moderate	to	low	activity	against	the	examined	microorganisms.	
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1.	Introduction	
	
In	 recent	 years,	 there	 has	 been	 increasing	 interest	 in	 the	
chemistry	 of	 pyridazine	 family	 of	 heterocycles	 due	 to	 their	
diverse	 biological	 significance	 studied	 in	 large	 number	 of	
papers	[1],	this	variety	of	biological	activities	includes	anti‐HIV	
[2],	anti‐tobacco	mosaic	virus	Tobacco	Mosaic	Virus	(TMV)	[3],	
antidepressant	 [4],	 antiviral	 [5],	 anti‐cancer	 [6],	 analgesic,	
anti‐inflammatory	 [7],	 and	 selective	 CB2	 agonists	 for	 the	
treatment	of	inflammatory	pain	[8].	
Moreover,	 the	chemistry	of	1,2,4‐triazoles	and	their	 fused	
heterocyclic	 derivatives	have	 received	 considerable	 attention	
owing	 to	 their	 synthetic	 and	 effective	 biological	 importance,	
such	 as	 antitumor,	 anti‐inflammatory,	 antimicrobial,	 anti‐
thrombotic	 and	 anticonvulsant	 activities	 [9],	 also	 a	 large	
number	of	 triazole‐containing	 ring	systems	exhibit	 antifungal	
and	 antiviral	 properties	 [10].	 Sulfonamide	 group	 forms	 the	
bioactive	moiety	of	many	therapeutic	agents	such	as	diuretics,	
antidiabetics,	 antibiotics,	 and	 antibacterials	 [11‐16].	 So,	 our	
efforts	 were	 directed	 towards	 the	 synthesis	 of	 new	
heterocyclic	 compounds	 containing	 pyridazine	 moiety	 with	
anticipated	biological	activities.	In	this	paper,	the	synthesis	of	
new	 pyridazine	 and	 triazolopyridazine	 derivatives	 carrying	
sulfonamide	 groups	 is	 reported.	 These	 compounds	 were	
characterized	 by	 various	 spectroscopic	 methods.	 Antimicro‐
bial	 activities	 for	 some	 derivatives	 were	 assessed	 against	
representative	 Gram	 positive	 bacteria	 (Micrococcus	 luteus,	
Staphylococcus	 aureus),	 Gram	 negative	 bacteria	 (Escherichia	
coli)	and	fungi	(Candida	albicans).	
	
2.	Experimental	
	
2.1.	Chemistry	
	
All	 melting	 points	 were	 determined	 in	 open	 glass	
capillaries	and	are	uncorrected.	IR	spectra	were	recorded	on	a	
Bruker	 Vector	 22	 Germany	 spectrometer	 (KBr).	 1H	 NMR	
spectra	 were	 recorded	 on	 Varian	 Gemini	 200	 MHz	
spectrometer	and	13C	NMR	spectra	on	JMS‐AX500	(125	MHz),	
using	 tetramethylsilane	 (TMS)	 as	 an	 internal	 reference.	 The	
electron	 impact	 mass	 spectra	 were	 obtained	 at	 70	 eV	 using	
Shimadzu	 QP‐2010	 Plus	 mass	 spectrometer.	 Reactions	 were	
monitored	 by	 thin	 layer	 chromatography	 (TLC)	 on	 silica	 gel	
60F254	aluminum	sheets	(Merck)	and	pots	were	detected	by		
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UV	 lamp	 at	 254‐365	 nm.	 The	 synthesis	 of	 4,5,6‐triphenyl	
pyridazine‐3(2H)‐thione	 (1)	 [17],	 6,7,8‐triphenyl‐[1,2,4]	
triazolo[4,3‐b]pyridazine‐3‐thiol	 (4)	 [18]	 and	 their	 corres‐
ponding	sulfonylchloride	derivatives	2	and	5	were	performed	
according	to	known	procedure	[19].	
	
2.2.	Antimicrobial	activity	
	
Antimicrobial	activity	study	was	performed	using	standard	
cultures	 of	 Micrococcus	 luteus	 (ATCC10240),	 Staphylococcus	
aureus	 (ATCC6538P),	 Escherichia	 coli	 (ATCC10536)	 and	
Candida	 albicans	 (ATCC2091).	 Micrococcus	 luteus,	
Staphylococcus	 aureus Staphylococcus	 aureus	 and	 E.	 coli	
cultures	were	incubated	in	Nutrient	Broth	(NB)	(Difco),	while	
Candida	albicans	was	 incubated	 in	Sabouraud	Dextrose	Broth	
(SDB)	 (Difco),	 dimethylformamide	was	 used	 as	 a	 solvent	 for	
tested	 compounds.	 A	 blank	 disc	 impregnated	 with	
dimethylformamide	 followed	 by	 drying	 off	 was	 used	 as	 a	
negative	 control.	 Sulfadoxine,	 sulfadimidine	 and	 nystatin	 at	
concentration	 of	 0.4	mg/0.1	mL	 in	 dimethylformamide	were	
used	as	positive	control	(Table	1).	
	
2.3.	Synthesis	
	
2.3.1.	Preparation	of	4,5,6‐triphenylpyridazine‐3‐sulfonyl	
chloride	(2)	
	
In	 a	 solution	 of	 3‐mercapto	 derivative	 1	 (2.9	 mmol)	 in	
acetic	 acid	 (19	 mL)	 and	 water	 (1	 mL),	 chlorine	 gas	 was	
bubbled	at	0	°C	for	1	h.	The	reaction	mixture	was	poured	into	
water	(250	mL)	portion‐wise	with	stirring;	the	precipitate	was	
filtered,	washed	with	water	several	times	and	dried	to	give	3‐
sulfonylchloride	 derivative	 2	 in	 92%	 yield.	 The	 respective	
crude	 sulfonylchloride	 was	 used	 in	 the	 next	 step	 without	
further	purification	(Scheme	1).	
	
2.3.2.	Preparation	of	4,5,6‐triphenylpyridazine‐3‐
sulfonamide	derivatives	(3a‐i)	
	
To	a	solution	of	sulfonylchloride	derivative	2	(2.46	mmol)	
in	 benzene	 (20	 mL),	 substituted	 amine	 was	 added	 (2.46	
mmol),	 the	 reaction	 mixture	 was	 refluxed	 for	 3	 hours,	 the	
solvent	 was	 evaporated	 in	 vacuo,	 the	 solid	 product	 was	
collected	and	recrystallized	from	ethanol	(Scheme	1).	
4,5,6‐Triphenylpyridazine‐3‐sulfonohydrazide	 (3a):	 Prepa‐
red	from	hydrazine	hydrate.	Color:	White	crystals.	Yield:	85%.	
M.p.:	295‐298	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3390	(NH),	3230,	3150	
(NH2),	 1617	 (C=N),	 1350,	 1160	 (SO2).	 1H	 NMR	 (200	 MHz,	
DMSO‐d6,	δ,	ppm):	8.10	(s,	1H,	NH),	7.89‐7.42	(m,	15H,	Ar‐H),	
2.80	(s,	2H,	NH2).	13C	NMR	(125	MHz,	DMSO‐d6,	δ,	ppm):	158.9	
(C‐6),	 157.9	 (C‐3),	 137.4	 (C‐4),	 136.7	 (C‐5),	 135.7	 (C‐5),	 134	
(C‐4),	 130.2‐128.5	 (3Ph).	MS	 (m/z	 (%)):	 402	 (M+,	 7.87),	 338	
(M+‐SO2,	 100,	 F1),	 322	 (F1‐NH2,	 39.29,	 F2),	 296	 (F2	 ‐CH2=NH,	
2.81),	236	(F2	–Ph,	3.47).	Anal.	calcd.	for	C22H18N4O2S:	C,	65.65;	
H,	4.51;	N,	13.92.	Found:	C,	65.50;	H,	4.35;	N,	13.76%.	
N‐(2‐Hydroxyethyl)‐4,	 5,	 6‐triphenylpyridazine‐3‐sulfon	
amide	 (3b):	 Prepared	 from	 ethanolamine.	 Color:	 White	
crystals.	 Yield:	 75.4%.	M.p.:	 285‐287	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3420	(OH),	3285	(NH),	2921	(CHaliph),	1639	(C=N),	1368,	1167	
(SO2).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.30	(s,	1H,	NH),	
7.89‐7.42	 (m,	 15H,	 Ar‐H),	 2.90	 (t,	 2H,	 CH2NH),	 3.50	 (t,	 2H,	
CH2OH),	 3.75	 (s,	 1H,	 OH).	 13C	 NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	
ppm):	157.9	(C‐6),	156.9	(C‐3),	136.4	(C‐4),	135.7(C‐5),	134.7	
(C‐5),	133	(C‐4),	129.2‐127.5	(Ar‐C),	61.1	(C‐OH),	46.5	(C‐NH).	
MS	 (m/z	 (%)):	 431	 (M+,	 8.02),	 386	 (M+‐CH2CH2OH,	 7.39,	 F1),	
371	 (F1‐NH2,	8.56,	F2),	346	 (F2‐N2,	9.18,	F3),	271	 (F3‐Ph,	7.62,	
F4).	 Anal.	 calcd.	 for	 C24H21N3O3S:	 C,	 66.80;	 H,	 4.91;	 N,	 9.74.	
Found:	C,	66.65;	H,	4.76;	N,	9.60%.	
4‐((4,5,6‐Triphenylpyridazin‐3‐yl)sulfonyl)morpholine	 (3c):	
Prepared	 from	 morpholine.	 Color:	 White	 crystals.	 Yield:	
80.3%.	M.p.:	 188‐190	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3057	 (CHarom),	
2915	 (CHaliph),	 1624	 (C=N),	 1351,	 1158	 (SO2).	 1H	 NMR	 (200	
MHz,	DMSO‐d6,	δ,	ppm):	7.89‐7.42	(m,	15H,	Ar‐H),	2.98	(t,	4H,	
CH2NCH2),	3.85	(t,	4H,	CH2OCH2).	13C	NMR	(125	MHz,	DMSO‐d6,	
δ,	 ppm):	 158.4	 (C‐6),	 157.4	 (C‐3),	 136.9	 (C‐4),	 136.2	 (C‐5),	
135.2	(C‐5),	134.0	(C‐4),	130.1‐128.2	(Ar‐C),	67.3	(C‐O‐C),	49.2	
(C‐N‐C).	MS	 (m/z	 (%)):	 455	 (M+‐2,	 0.62),	 393	 (M+	 ‐SO2,	 4.54,	
F1),	308	(F1	‐NC4H8O,	88.63,	F2),	280	(F2	‐N2,	4.40).	Anal.	calcd.	
for	C26H23N3O3S:	C,	68.25;	H,	5.07;	N,	9.18.	Found:	C,	68.10;	H,	
4.90;	N,	9.01%.	
N‐Benzyl‐4,	5,	6‐triphenylpyridazine‐3‐sulfonamide	(3d):	
Prepared	 from	 benzyl	 amine.	 Color:	 White	 crystals.	 Yield:	
76.9%.	M.p.:	275	‐277	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3381	(NH),	2890	
(CHaliph),	 1636	 (C=N),	 1377,	 1146	 (SO2).	 1H	 NMR	 (200	 MHz,	
DMSO‐d6,	δ,	ppm):	8.54	(s,	1H,	NH),	7.31‐7.10	(m,	15H,	Ar‐H),	
7.08‐7.05	(m,	5H,	Ar‐H),	4.10	(s,	2H,	CH2).	13C	NMR	(125	MHz,	
DMSO‐d6,	δ,	ppm):	157.9	(C‐6),	156.9	(C‐3),	136.4	(C‐4),	135.7	
(C‐5),	 134.7	 (C‐5),	 133.0	 (C‐4),	 129.2‐126.7	 (Ar‐C),	 48.5	 (C‐
NH).	MS	(m/z	(%)):	478	(M++1,	17.29),	341	(100).	Anal.	calcd.	
for	C29H23N3O2S:	C,	72.93;	H,	4.85;	N,	8.80.	Found:	C,	72.79;	H,	
4.70;	N,	8.65%	
N,	4,	5,	6‐Tetraphenylpyridazine‐3‐sulfonamide	(3e):	Prepa‐
red	from	aniline.	Color:	White	crystals.	Yield:	92.6%.	M.p.:	290‐
292	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3316	 (NH),	 3036	 (CHarom),	 1644	
(C=N),	1354,	1222	(SO2).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	
8.10	(s,	1H,	NH),	7.89‐6.82	(m,	20H,	Ar‐H).	13C	NMR	(125	MHz,	
DMSO‐d6,	δ,	ppm):	158.9	(C‐6),	157.9	(C‐3),	137.4	(C‐4),	136.7	
(C‐5),	 135.7	 (C‐5),	 134.0	 (C‐4),	 129.2‐119.4	 (Ar‐C).	 MS	 (m/z	
(%)):	 464	 (M+,	 30.6),	 370	 (M+‐NHPh,	 0.72,	 F1),	 308	 (F1‐SO2,	
1.14,	F2),	2804	(F2‐N2,	3.75,	F3).	Anal.	calcd.	for	C28H21N3O2S:	C,	
72.55;	H,	4.57;	N,	9.06.	Found:	C,	72.40;	H,	4.41;	N,	8.83%.	
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4,5,6‐Triphenyl‐N‐(o‐tolyl)pyridazine‐3‐sulfonamide	(3f):	
Prepared	 from	o‐tolidine.	Color:	White	 crystals.	 Yield:	81.1%.	
M.p.:	 280‐282	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3350	 (NH),	 2915	
(CHaliph),	 1640	 (C=N),	 1304,	 1137	 (SO2).	 1H	 NMR	 (200	 MHz,	
DMSO‐d6,	δ,	ppm):	9.10	(s,	1H,	NH),	7.94‐7.42	(m,	19H,	Ar‐H),	
3.1	(s,	3H,	CH3).	 13C	NMR	(125	MHz,	DMSO‐d6,	δ,	ppm):	158.9	
(C‐6),	157.9	(C‐3),	137.4	(C‐4),	136.7	(C‐5),	135.7	(C‐5),	134.0	
(C‐4),	130.2‐128.5	(Ar‐H),	19.3	(CH3).	MS	(m/z	(%)):	477	(M+,	
37.82),	308	(M+‐SO2NHC6H4CH3,	7.64,	F1),	280	(F1‐N2,	7.64,	F2),	
204	 (F2‐Ph,	 16.77,	 F3),	 106	 (F3‐C8H8,	 100,	F4).	Anal.	 calcd.	 for	
C29H23N3O2S:	C,	72.93;	H,	4.85;	N,	8.80.	Found:	C,	72.88;	H,	4.70;	
N,	8.65%.	
4,5,6‐Triphenyl‐N‐(m‐tolyl)pyridazine‐3‐sulfonamide	 (3g):	
Prepared	from	m‐tolidine.	Color:	White	crystals.	Yield:	76.9%.	
M.p.:	 218‐220	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3279	 (NH),	 3107	
(CHarom),	2918	(CHaliph),	1636	(C=N),	1365,	1163	(SO2).	1H	NMR	
(200	MHz,	DMSO‐d6,	 δ,	 ppm):	 9.10	 (s,	 1H,	NH),	7.94‐6.70	 (m,	
19H,	Ar‐H),	3.20	(s,	3H,	CH3).	13C	NMR	(125	MHz,	DMSO‐d6,	δ,	
ppm):	159.9	(C‐6),	158.9	(C‐3),	138.4	(C‐4),	137.7	(C‐5),	136.7	
(C‐5),	 135.0	 (C‐4),	 129.2‐119.4	 (Ar‐C),	 22.5	 (CH3).	 MS	 (m/z	
(%)):	 477	 (M+,	 1.96),	 387	 (M+‐C6H4CH3,	 0.4,	 F1),	 323	 (F1‐SO2,	
100,	F2),	308	(F2‐NH2,	0.92,	F3),	280	(F3‐N2,	3.82,	F4),	204	(F4‐
Ph,	 8.01,	 F5),	 106	 (F5‐C8H8,	 0.67,	 F6).	 	 Anal.	 calcd.	 for	
C29H23N3O2S:	C,	72.93;	H,	4.85;	N,	8.80.	Found:	C,	72.90;	H,	4.72;	
N,	8.63%.	
N‐(2‐Chlorobenzyl)‐4,5,6‐triphenylpyridazine‐3‐sulfonamide	
(3h):	 Prepared	 from	 2‐chlorobenzylamine.	 Color:	 White	
crystals.	 Yield:	 79.3%.	M.p.:	 211‐213	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3390	 (NH),	 2885	 (CHaliph),	 1642	 (C=N),	 1376,	 1105	 (SO2).	 1H	
NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.54	(s,	1H,	NH),	7.64‐7.51	
(m,	15H,	Ar‐H),	7.43‐7.40	(m,	4H,	Ar‐H),	4.10	(s,	2H,	CH2).	13C	
NMR	 (125	MHz,	 DMSO‐d6,	 δ,	 ppm):	 159.9	 (C‐6),	 158.9	 (C‐3),	
138.4	(C‐4),	137.7	(C‐5),	136.7	(C‐5),	134.0	(C‐4),	129.2‐126.6	
(4Ph),	43.2	 (C‐NH).	MS	 (m/z	 (%)):	512	 (M+,	11.56),	476	 (M+‐
HCl,	 100,	 F1),	 387	 (F1‐CH2Ph,	 15.34,	 F2),	 370	 (F2‐NH2,	 14.36,	
F3),	 307	 (F3‐SO2,	 20.42,	 F4),	 323	 (F2‐SO2,	 57.84,	 F5),	 308	 (F5‐
NH2,	0.92,	F6).	Anal.	calcd.	for	C29H22ClN3O2S:	C,	68.03;	H,	4.33;	
N,	8.21.	Found:	C,	67.86;	H,	4.15;	N,	8.04%.	
N‐(Naphthalen‐1‐yl)‐4,	 5,	 6‐triphenylpyridazine‐3‐sulfon	
amide	 (3i):	 Prepared	 from	 α‐naphthylamine.	 Color:	 White	
crystals.	Yield:	86.09%.	M.p.:	228‐230	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3350	 (NH),	 3034	 (CHarom),	 1628	 (C=N),	 1391,	 1120	 (SO2).	 1H	
NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	10.10	(s,	1H,	NH),	8.20‐7.41	
(m,	22H,	Ar‐H).	 13C	NMR	(125	MHz,	DMSO‐d6,	 δ,	ppm):	157.9	
(C‐6),	 156.9	 (C‐3),	 142	 (C‐1),	 136.4	 (C‐4),	 135.7	 (C‐5),	 134.7	
(C‐5),	 133.0	 (C‐4),	 129.2‐127.5	 (Ar‐C),	 127‐109	 (1‐Naphthyl‐
C).	 	 MS	 (m/z	 (%)):	 513	 (M+,	 26.59),	 449	 (M+‐SO2,	 16.12,	 F1),	
323	 (F1‐C10H7,	 27.74,	 F2),	 307	 (F2‐NH2,	 9.51,	 F3),	 280	 (F3‐N2,	
7.71,	F4).	Anal.	calcd.	for	C32H23N3O2S:	C,	74.83;	H,	4.51;	N,	8.18.	
Found:	C,	74.68;	H,	4.36;	N,	8.03%.	
	
2.3.3.	6,7,8‐Triphenyl‐[1,2,4]triazolo[4,3‐b]pyridazine‐3‐
sulfonyl	chloride	(5)	
	
To	 a	 solution	 of	 3‐mercapto	 derivative	 4	 (2.6	 mmol)	 in	
acetic	 acid	 (19	 mL)	 and	 water	 (1	 mL),	 chlorine	 gas	 was	
bubbled	at	0	°C	for	1	h.	The	reaction	mixture	was	poured	into	
water	(250	mL)	portion‐wise	with	stirring;	the	precipitate	was	
filtered,	washed	with	water	several	times	and	dried	to	give	3‐
sulfonylchloride	 derivative	 5	 yield	 90.5%.	 The	 respective	
crude	 sulfonylchloride	 was	 used	 in	 the	 next	 step	 without	
further	purification.	 Color:	White	 crystals.	Yield:	 90.5%.	M.p.:	
130‐132	°C	(Scheme	2).	
	
2.3.4.	3‐Sustituted	sulfamoyl‐6,7,8‐triphenyl	[1,2,4]triazolo	
[4,3‐b]pyridazine	(6a‐i)	
	
To	a	solution	of	sulfonyl	chloride	derivative	5	(2.20	mmol)	
in	 benzene	 (20	 mL),	 substituted	 amine	 was	 added	 (2.20	
mmol),	 the	 reaction	 mixture	 was	 refluxed	 for	 3	 hours,	 the	
solvent	was	concentrated,	the	solid	product	was	collected	and	
recrystallized	from	ethanol	(Scheme	2).		
6,7	,	8‐Triphenyl	[1,	2,	4]triazolo[4,	3‐b]pyridazine‐3‐sulfono	
hydrazide	 (6a):	 Prepared	 from	 hydrazine	 hydrate.	 Color:	
White	 crystals.	Yield:	 80.7%.	M.p.:	 260‐262	 °C.	 FT‐IR	 (KBr,	 ν,	
cm‐1):	3350	(NH),	1621	(C=N),	1322,	1171	(SO2).	1H	NMR	(200	
MHz,	DMSO‐d6,	 δ,	 ppm):	 8.20	 (s,	 1H,	NH),	 7.80‐7.41	 (m,	 15H,	
Ar‐H),	2.9	(s,	2H,	NH2).	13C	NMR	(125	MHz,	DMSO‐d6,	δ,	ppm):	
155.7	(C‐8),	150.1	(C‐5),	147.0	(C‐3),	135.4	(C‐6),	135.0	(C‐6),	
134.4	 (C‐7),	 133.7	 (C‐7),	 132.0	 (C‐8),	 128.2‐126.5	 (Ar‐C).	MS	
(m/z	(%)):	442	(M+,	3.17),	426	(M+‐NH2,	1.67,	F1),	411	(F1‐NH2,	
3.44,	 F2).	 Anal.	 calcd.	 for	 C23H18N6O2S:	 C,	 62.43;	 H,	 4.10;	 N,	
18.99.	Found:	C,	62.28;	H,	3.93;	N,	18.82%	
N‐(2‐Hydroxyethyl)‐6,	7,	8‐triphenyl	[1,	2,	4]triazolo[4,	3‐b]	
pyridazine‐3‐sulfonamide	 (6b):	 Prepared	 from	 ethanolamine.	
Color:	 White	 crystals.	 Yield:	 55.2%.	 M.p.:	 148‐150	 °C.	 FT‐IR	
(KBr,	 ν,	 cm‐1):	 3416	 (OH),	 3325	 (NH),	 2914	 (CHaliph),	 1640	
(C=N),	1302,	1100	(SO2).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	
8.20	(s,	1H,	NH),	7.80‐7.41	(m,	15H,	Ar‐H),	4.10	(t,	2H,	CH2OH),	
3.80	(s,	1H,	OH),	2.9	(t,	2H,	CH2NH).	13C	NMR	(125	MHz,	DMSO‐
d6,	 δ,	 ppm):	 155.7	 (C‐8),	 150.1	 (C‐5),	 147	 (C‐3),	 135.4	 (C‐6),	
135.0	(C‐6),	134.4	(C‐7),	133.7	(C‐7),	132.0	(C‐8),	128.2‐126.5	
(Ar‐C),	 59.1	 (C‐OH),	 44.5	 (C‐NH).	 MS	 (m/z	 (%)):	 472	 (M++1,	
4.27),	 347	 (M+‐SO2NHCH2CH2OH,	 4.81,	 F1),	 348	 (F1‐C4H8NO,	
59.56,	F2),	324	(F2‐N2,	4.40,	F3).	Anal.	calcd.	for	C25H21N5O3S:	C,	
63.68;	H,	4.49;	N,	14.85.	Found:	C,	63.50;	H,	4.31;	N,	14.70%.	
4‐((6,	 7,	 8‐Triphenyl‐[1,	 2,	 4]triazolo[4,	 3‐b]pyridazin‐3‐yl)	
sulfonyl)morpholine	 (6c):	 Prepared	 from	 morpholine.	 Color:	
White	 crystals.	Yield:	 84.1%.	M.p.:	 223‐225	 °C.	 FT‐IR	 (KBr,	 ν,	
cm‐1):	 2920	 (CHaliph),	 1622	 (C=N),	 1309,	 1115	 (SO2).	 1H	NMR	
(200	MHz,	DMSO‐d6,	δ,	ppm):	7.80‐7.41	(m,	15H,	Ar‐H),	4.10	(t,	
4H,	CH2‐O‐CH2),	3.50	(t,	4H,	CH2‐N‐CH2).	
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Table	1.	Anti‐microbial	activity	of	synthesized	compounds	*.	
Compound	 Micrococcus	luteus	 Staphylococcus	aureus Escherichia	coli Candida	albicans
3a	 +++	 ++ +++ +++	
3b	 +++	 ++	 +++	 +++	
3c	 +++	 ++	 +++	 +++	
3d	 ++	 +++	 ++	 +++	
3e	 +++	 ++	 ++	 +++	
3f	 +++	 ++ ++ +++	
3g	 +++	 ++ ++ +++	
3h	 +++	 ++ ++ +++	
3i	 +++	 ++ ++ +++	
6a	 ++++	 +++ +++ +++	
6b	 ++++	 ++ ++ +++	
6c	 +	 ++ + +++	
6d	 ++	 ++	 +++	 +++	
6e	 +++	 + ++ +++	
6f	 +	 ++	 +	 ++	
6g	 ++++	 +	 +	 ++++	
6h	 ++	 + + +++	
6i	 ++++	 ++ ++++ +++	
DMF	 ‐	 ‐	 ‐	 ‐	
Sulfadoxine	 +++	 +++ ++ +++	
Sulfadimidine	 +++	 +++	 ++	 +++	
Nystatin	 ‐	 ‐	 ‐	 ++++	
*	Values	are	mean	inhibition	zone	(mm)	of	two	replicates,	25‐35	mm	=	++++,	18‐24	mm	=	+++,	11‐16	mm	=	++,	≤10	mm	=	+,	‐	=	negative	inhibition.	
	
	
13C	NMR	(125	MHz,	DMSO‐d6,	δ,	ppm):	155.7	 (C‐8),	150.1	
(C‐5),	147.0	(C‐3),	135.4	(C‐6),	135.0	(C‐6),	134.4	(C‐7),	133.7	
(C‐7),	132.0	(C‐8),	128.2‐126.5	(Ar‐C),	64.3	(C‐O‐C),	46.2	(C‐N‐
C).	MS	(m/z	 (%)):	497	(M+,	0.75),	433	(M+‐SO2,	2.72,	F1),	348	
(F1‐C4H8NO,	 59.56,	 F2),	 324	 (F2‐N2,	 4.40,	 F3).	 Anal.	 calcd.	 for	
C27H23N5O3S:	 C,	 65.17;	 H,	 4.66;	 N,	 14.08.	 Found:	 C,	 65.01;	 H,	
4.50;	N,	13.92%.	
N‐Benzyl‐6,	7,	8‐triphenyl‐[1,	2,	4]triazolo[4,	3‐b]pyridazine‐
3‐sulfonamide	(6d):	Prepared	from	benzylamine.	Color:	White	
crystals.	 Yield:	 69.5%.	M.p.:	 237‐239	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3390	 (NH),	 2891	 (CHaliph),	 1624	 (C=N),	 1312,	 1151	 (SO2).	 1H	
NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.20	(s,	1H,	NH),	7.80‐7.41	
(m,	15H,	Ar‐H),	7.35‐7.25	(m,	5H,	Ar‐H),	3.50	(s,	2H,	CH2).	13C	
NMR	 (125	MHz,	 DMSO‐d6,	 δ,	 ppm):	 157.7	 (C‐8),	 152.1	 (C‐5),	
149.0	(C‐3),	137.4	(C‐6),	137.0	(C‐6),	136.4	(C‐7),	135.7	(C‐7),	
134.0	 (C‐8),	 130.2‐127.7	 (Ar‐C),	 47.2	 (C‐NH).	 MS	 (m/z	 (%)):	
516	 (M+‐1,	 3.32),	 425	 (M+‐CH2C6H5,	 3.23).	 Anal.	 calcd.	 for	
C30H23N5O2S:	 C,	 69.61;	 H,	 4.48;	 N,	 13.53.	 Found:	 C,	 69.44;	 H,	
4.30;	N,	13.37%.	
N,	 6,	 7,	8‐Tetraphenyl‐[1,	 2,	 4]triazolo[4,	 3‐b]pyridazine‐3‐
sulfonamide	(6e):	Prepared	from	aniline.	Color:	White	crystals.	
Yield:	62.5%.	M.p.:	261‐263	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3360	(NH),	
3054	 (CHarom),	 1640	 (C=N),	 1360,	 1161	 (SO2).	 1H	 NMR	 (200	
MHz,	DMSO‐d6,	 δ,	 ppm):	 8.40	 (s,	 1H,	NH),	 7.31‐7.10	 (m,	 15H,	
Ar‐H),	7.08‐7.05	(m,	5H,	Ar‐H).	13C	NMR	(125	MHz,	DMSO‐d6,	δ,	
ppm):	157.7	(C‐8),	152.1	(C‐5),	149.0	(C‐3),	137.5	(C‐6),	137.0	
(C‐6),	136.4	(C‐7),	135.7	(C‐7),	134.0	(C‐8),	129.5‐119.4	(Ar‐C).	
MS	 (m/z	 (%)):	 503	 (M+,	 19.27),	 439	 (M+‐SO2,	 50.47,	 F1),	 348	
(F1‐NHPh,	14.31,	F2).	Anal.	calcd.	for	C29H21N5O2S:	C,	69.17;	H,	
4.20;	N,	13.91.	Found:	C,	69.00;	H,	4.03;	N,	13.76%.	
6,7,8‐Triphenyl‐N‐(o‐tolyl)‐[1,2,4]triazolo[4,	3‐b]pyridazine‐
3‐sulfonamide	 (6f):	 Prepared	 from	 o‐toluidine.	 Color:	 White	
crystals.	 Yield:	 67.2%.	M.p.:	 268‐270	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3396	 (NH),	 2962	 (CHaliph),	 1635	 (C=N),	 1342,	 1165	 (SO2).	 1H	
NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.30	(s,	1H,	NH),	7.32‐7.22	
(m,	15H,	Ar‐H),	6.90‐6.80	(m,	4H,	Ar‐H),	2.28	(s,	3H,	CH3).	13C	
NMR	 (125	MHz,	 DMSO‐d6,	 δ,	 ppm):	 157.7	 (C‐8),	 152.1	 (C‐5),	
149.0	(C‐3),	137.5	(C‐6),	137.0	(C‐6),	136.4	(C‐7),	135.7	(C‐7),	
134.0	(C‐8),	129.5‐123.7	(Ar‐C),	18.3	(CH3).	MS	(m/z	(%)):	517	
(M+,	33.45),	453	(M+‐SO2,	58.90,	F1),	438	(F1‐NH2,	5.48,	F2),	348	
(F2‐C6H4CH3,	 1.20,	 F3),	 324	 (F3‐N2,	 1.60,	 F4).	 Anal.	 calcd.	 for	
C30H23N5O2S:	 C,	 69.61;	 H,	 4.48;	 N,	 13.53.	 Found:	 C,	 69.44;	 H,	
4.30;	N,	13.36%.	
6,7,8‐Triphenyl‐N‐(m‐tolyl)‐[1,2,4]triazolo[4,3‐b]pyridazine‐
3‐sulfonamide	 (6g):	 Prepared	 from	m‐toluidine.	 Color:	White	
crystals.	 Yield:	 76.3%.	M.p.:	 210‐212	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3270	 (NH),	 2916	 (CHaliph),	 1638	 (C=N),	 1381,	 1161	 (SO2).	 1H	
NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.20	(s,	1H,	NH),	7.32‐7.22	
(m,	15H,	Ar‐H),	6.90‐6.80	(m,	4H,	Ar‐H),	2.38	(s,	3H,	CH3).	 13C	
NMR	 (125	MHz,	 DMSO‐d6,	 δ,	 ppm):	 157.7	 (C‐8),	 152.1	 (C‐5),	
149.0	(C‐3),	137.5	(C‐6),	137.0	(C‐6),	136.4	(C‐7),	135.7	(C‐7),	
134.0	(C‐8),	129.5‐117.4	(Ar‐C),	12.3	(CH3).	MS	(m/z	(%)):	517	
(M+,	 37.78),	 453	 (M+‐SO2,	 19.79,	 F1),	 348	 (F1‐NHC6H4CH3,	
19.93,	 F2).	 Anal.	 calcd.	 for	 C30H23N5O2S:	 C,	 69.61;	 H,	 4.48;	 N,	
13.53.	Found:	C,	69.45;	H,	4.31;	N,	13.35%.	
N‐(2‐Chlorobenzyl)‐6,	7,	8‐triphenyl‐[1,	2,	4]triazolo[4,	3‐b]	
pyridazine‐3‐sulfonamide	 (6h):	 Prepared	 from	2‐chlorobenzyl	
amine.	Color:	White	crystals.	Yield:	75%.	M.p.:	218‐220	°C.	FT‐
IR	(KBr,	ν,	cm‐1):	3330	(NH),	2891	(CHaliph),	1588	(C=N),	1322,	
1109	(SO2).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.20	(s,	1H,	
NH),	7.80‐7.41	(m,	15H,	Ar‐H),	7.30‐7.10	(m,	4H,	Ar‐H),	3.60	(s,	
2H,	CH2).	 13C	NMR	 (125	MHz,	DMSO‐d6,	 δ,	ppm):	157.7	 (C‐8),	
152.1	(C‐5),	149.0	(C‐3),	137.5	(C‐6),	137.0	(C‐6),	136.4	(C‐7),	
135.7	 (C‐7),	134.0	 (C‐8),	 130.2‐127.4	 (Ar‐C),	43.1	 (C‐NH).	MS	
(m/z	 (%)):	 552	 (M+,	 38.06),	 106	 (100).	 	 Anal.	 calcd.	 for	
C30H22ClN5O2S:	C,	65.27;	H,	4.02;	N,	12.69.	Found:	C,	65.10;	H,	
3.88;	N,	12.51%.	
N',	6,	7,	8‐Tetraphenyl‐[1,	2,	4]triazolo[4,	3‐b]pyridazine‐3‐
sulfonohydrazide	(6i):	Prepared	from	phenyl	hydrazine.	Color:	
White	 crystals.	Yield:	 60.3%.	M.p.:	 188‐190	 °C.	 FT‐IR	 (KBr,	 ν,	
cm‐1):	 3337,	 3202	 (2NH),	 3033	 (CHarom),	 1640	 (C=N),	 1306,	
1159	 (SO2).	 1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	8.0	 (s,	1H,	
NH),	7.80‐7.41	(m,	15H,	Ar‐H),	7.37‐6.90	(m,	5H,	Ar‐H),	4.20	(s,	
1H,	NHPh).	13C	NMR	(125	MHz,	DMSO‐d6,	δ,	ppm):	157.7	(C‐8),	
152.1	(C‐5),	149.0	(C‐3),	137.5	(C‐6),	137.0	(C‐6),	136.4	(C‐7),	
135.7	 (C‐7),	 134.0	 (C‐8),	 130.2‐115.4	 (Ar‐C).	 MS	 (m/z	 (%)):	
514	 (M+‐4,	 9.59),	 105	 (100).	 Anal.	 calcd.	 for	 C29H22N6O2S:	 C,	
67.17;	H,	4.28;	N,	16.21.	Found:	C,	67.00;	H,	4.11;	N,	16.04%.	
	
3.	Results	and	discussion	
	
3.1.	Synthesis		
	
The	 sulfonamide	 derivatives	 as	 the	 target	 compounds	
depicted	 in	 (Scheme	1	 and	2)	were	obtained	by	 allowing	 the	
pyridazinethiol	derivatives	1	 [17]	and	 triazolopyridazinethiol	
4	[18]	 to	oxidatively	chlorinate	with	chlorine	gas	 in	presence	
of	90%	acetic	acid	at	0	°C,	the	corresponding	sulfonyl	chlorides	
2	and	5	were	obtained	[19].	
Because	 of	 the	 instability	 of	 sulfonyl	 chlorides,	 the	 crude	
products	 of	 sulfonyl	 chloride	 derivatives	 2	 and	 5	 were	
converted	directly	to	the	more	stable	sulfonamides	3	and	6	by	
amidation.	 The	 sulfonyl	 chloride	 derivatives	 2	 and	 5	 were	
identified	by	their	corresponding	sulfonamides.	The	IR	spectra	
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of	 compounds	 3a‐i	 and	 6a‐i	 are	 characterized	 by	 bands	 at	
3300‐3200	 cm‐1	 (NH),	 and	 characteristic	 absorption	bands	 in	
the	regions	of	1134‐1152	and	1358‐1377	cm‐1	corresponding	
to	 symmetrical	 and	 asymmetrical	 vibrations	 of	 SO2	 group.	
Moreover,	for	SAR	study,	we	aimed	to	synthesize	a	new	series	
of	 sulfonamides	 3a‐i	 and	 6a‐i	 to	 investigate	 the	 effect	 of	
attaching	triazole	ring	(of	the	known	pharmacological	activity)	
to	 pyridazine	 nucleus	 upon	 the	 required	 activity	 as	
antimicrobial	 agents.	 The	 synthesized	 compounds	 were	
characterized	by	various	spectroscopic	methods	such	as	IR,	1H	
NMR,	 13C	NMR	and	MS,	elemental	and	spectral	analyses	of	all	
prepared	 compounds	 described	 are	 consistent	 with	 the	
assigned	structures.		
 
3.2.	Antimicrobial	activity	
	
Applying	the	agar	plate	diffusion	technique	[20],	the	newly	
synthesized	sulfonamide	derivatives	were	screened	in	vitro	for	
antimicrobial	 activity	 against	 Gram	 positive	 bacteria	
(Staphylococcus	aureus	and	Micrococcus	luteus),	Gram	negative	
bacteria	(Escherichia	coli)	and	yeast	(Candida	albicans).	In	this	
method,	a	standard	5	mm	diameter	sterilized	filter	paper	disc	
impregnated	 with	 the	 compounds	 (0.4	 mg/0.1	 mL	 of	
dimethylformamide)	was	placed	on	the	agar	plates	which	had	
previously	 been	 inoculated	 with	 the	 above	 organisms;	 The	
petri	dishes	were	 left	at	4	 °C	 for	2	h,	 then	 the	 injected	plates	
with	bacteria	were	incubated	at	37±0.1	°C	for	24	h,	and	those	
inoculated	with	fungi	were	incubated	at	25±0.1	°C	for	48	h.	At	
the	 end	 of	 the	 period,	 diameter	 of	 inhibition	 zones	 were	
measured	 in	 mm,	 these	 studies	 were	 performed	 in	 two	
replicates.	 The	 screening	 results	 given	 in	 Table	 1	 indicated	
that	all	the	compounds	exhibited	antimicrobial	activity	against	
all	the	test	organisms.	
	
4.	Conclusion	
	
In	 summary,	 we	 have	 developed	 a	 novel	 class	 of	
sulfonamide	 derivatives	 substituted	 with	 pyridazine	 and	
triazolopyridazine	 derivatives	 as	 potential	 antimicrobial	
agents	and	the	following	was	concluded:	compounds	6a,	b	and	
6g,	i	with	triazole	ring	fused	with	pyridazine	nucleus	showed	a	
remarkable	 antimicrobial	 activity	 against	Micrococcus	 luteus	
greater	 than	 that	of	 the	non‐condensed	pyridazine	nucleus	 in	
case	 of	 compounds	3a,	b	 and	3g,	 i.	This	 in	 turn	 reveals	 that	
there’s	a	significant	relation	between	activity	and	nature	of	the	
pyridazine	nucleus,	Rest	of	the	compounds	showed	moderate	
to	low	activity	against	the	examined	micro‐organisms.	
	
Acknowledgements	
	
The	authors	are	grateful	for	financial	support	of	this	work	
by	the	Academy	of	Scientific	Research	and	Technology,	Cairo,	
Egypt,	through	a	research	grant	no.	293/2005	titled	“Synthesis	
of	Biologically	Active	Organic	Compounds”.	
	
References	
	
[1]. Buonora,	 P.	 T.;	 Zhang,	 Q.;	 Sawko,	 J.;	 Westrum,	 L.	 J.	 Tetrahedron‐
Asymm.	2008,	19(1),	27‐30.		
[2]. Sweeney,	Z.	K.;	Dunn,	J.	P.;	Li,	Y.;	Heilek,	G.;	Dunten,	P.;	Elworthy,	T.	R.;	
Han,	X.	C.;	Harris,	S.	F.;	Hirschfeld,	D.	R.;	Hogg,	J.	H.;	Huber,	W.;	Kaiser,	
A.	C.;	Kertesz,	D.	J.;	Kim,	W.;	Mirzadegan,	T.;	Roepel,	M.	G.;	Saito,	Y.	D.;	
Silva,	T.	M.	P.	C.;	Swallow,	S.;	Tracy,	J.	L.;	Villasenor,	A.;	Vora,	H.;	Zhou,	
A.	S.;	Klumpp,	K.	Bioorg.	Med.	Chem.	Lett.	2008,	18,	4352‐4354.		
[3]. Zou,	X.	J.;	Jin,	G.	Y.	Chin.	J.	Org.	Chem.	2003,	23,	62‐65.		
[4]. Coelho,	A.;	Sotelo,	E.;	Ravina,	E.	Tetrahedron	2003,	59,	2477‐2484.		
[5]. Wang,	Z.;	Wang,	M.;	Yao,	X.;	Li,	Y.;	Tan,	J.;	Wang,	L.;	Qiao,	W.;	Geng,	Y.;	
Liu,	Y.;	Wang,	Q.	Eur.	J.	Med.	Chem.	2012,	54,	33‐41.		
[6]. Jiang,	 J.	 K.;	 Boxer,	 M.	 B.;	 Vander	 Heiden,	 M.	 G.;	 Shen,	 M.;	
Skoumbourdis,	A.	P.;	Southall,	N.;	Veith,	H.;	Leister,	W.;	Austin,	C.	P.;	
Park,	H.	W.;	 Inglese,	 J.;	Cantley,	 L.	C.;	Auld,	D.	S.;	Thomas,	C.	Bioorg.	
Med.	Chem.	Lett.	2010,	20,	3387‐3393.		
[7]. Refaat,	H.	M.;	Khalil,	O.	M.;	Kadry,	H.	H.	Arch.	Pharm.	Res.	2008,	30(7),	
803‐811.		
[8]. Gleave,	R.	J.;	Beswick,	P.	J.;	Brown,	A.	J.;	Giblin,	G.	M.	P.;	Goldsmith,	P.;	
Haslam,	C.	P.;	Mitchell,	W.	L.;	Nicholson,	N.	H.;	Page,	L.	W.;	Patel,	 S.;	
Roomans,	S.;	Slingsby,	B.	P.;	Swarbrick,	M.	E.	Bioorg.	Med.	Chem.	Lett.	
2010,	20,	465‐468.		
[9]. Xie,	Z.	F.;	Chai,	K.	Y.;	Piao,	H.	R.;	Kwak,	K.	C.;	Quan,	Z.	S.	Bioorg.	Med.	
Chem.	Lett.	2005,	15,	4803‐4805.		
[10]. Kritsanida,	 M.;	 Mouroutsou,	 A.;	 Marakos,	 P.;	 Pouli,	 N.;	
Papakonstantinou‐Garoufalias,	 S.;	 Annecouque,	 C.;	 Witvrouw,	 M.;	
Clercq,	E.	D.	Il	Farmaco	2002,	57,	253‐257.		
[11]. Lednicer,	 D.;	 Mitscher,	 L.	 A.;	 Georg,	 G.	 I.	 The	 organic	 chemistry	 of	
drug	synthesis,	Vol.	4,	Wiley,	New	York,	1990.		
[12]. El‐Gaby,	M.	S.	A.;	Micky,	J.	A.;	Taha,	N.	M;	El‐Sharief,	M.	A.	M.	S.	J.	Chin.	
Chem.	Soc.	2002,	49,	407‐	414.		
[13]. El‐Emary,	 T.	 I.;	 Al‐Muaikel,	 N.;	 Moustafa,	 O.	 S.	 Phosphorus	 Sulfur	
2002,	177,	195‐210.		
[14]. Deeb,	A.;		Mahgoub,	S.	Med.	Chem.	Res.	2014,	23,	4559‐4569.		
[15]. Hosny,	M.;	El‐Mariah,	F.;	Deeb,	A.	Phosphorus	Sulfur	2007,	182,	1475‐
1482.		
[16]. El‐Mariah,	F.;	Nassar,	E.;	Hosny,	M.;	Deeb,	A.	Phosphorus	Sulfur	2008,	
184,	92‐102.		
[17]. Deeb,	A.;	Said,	S.	Collect.	Czech.	Chem.	Commun.	1990,	55,	2795‐2799.		
[18]. Deeb,	A.;	Hassaneen,	M.;	Kotb,	M.	Heteroatom.	Chem.	2005,	12,	278‐
282.	
[19]. Deeb,	 A.;	 El‐Eraky,	 W.;	 El‐Awdan,	 S.;	 Mahgoub,	 S.	Med.	 Chem.	 Res.		
2014,	23,	34‐41.		
[20]. Bauer,	 A.	 W.;	 Kirby,	 M.	 D.	 K.;	 Sherries,	 J.	 C.;	 Turck,	 M.	 Am.	 J.	 Clin.	
Pathol.	1966,	45,	493‐496.		
	
	
